Introduction
============

Most patients with chronic HBV infection will develop hepatic cirrhosis. During the process of cirrhosis, hepatic fibrosis is an inevitable process in the development of chronic HBV infection to hepatic cirrhosis \[[@B1],[@B2]\]. Hepatic fibrosis is an early event in cirrhosis in patients with HBV infection. The gold standards for the diagnosis of hepatic fibrosis are pathological staging and classification \[[@B3]\]. However, biopsy of hepatic fibrosis in patients is limited by sampling error, poor compliance of patients, and difficulty in drawing the materials from live tissue \[[@B4],[@B5]\]. Methods which will achieve early diagnosis of hepatic fibrosis are still unknown.

The use of serum biomarkers for diagnosis of hepatic fibrosis has many advantages including being noninvasive, quick to acquire data, and provides confirmation of hepatic fibrosis in HBV infected patients faster \[[@B6]\]. However, there are no suitable serum biomarkers known that can serve as a reliable diagnostic biomarker for hepatic fibrosis.

Proteomics is an effective method to obtain high-flux protein data useful for identifying biomarkers \[[@B7]\]. In this study, in an effort to identify a serum biomarker of hepatic fibrosis, we used 2-DE and MALDI-TOF-MS to compare proteins which were differentially expressed in the serum of patients with hepatic fibrosis compared to HBV carriers. We identified two proteins, enolase-1 (α-enolase) and Thrombospondin-1 (TSP-1), which were differentially expressed and were chosen for further study. Our study suggests enolase-1 and TSP-1 play important roles in the development of hepatic fibrosis.

Materials and methods
=====================

Serum samples
-------------

Serum samples include 4 from patients with HBV hepatic fibrosis and another 4 from HBV carriers. All samples were from the First Xiangya Hospital of Central South University during the period of 2008.1 to 2010.12. All patients with HBV hepatic fibrosis were confirmed by pathological biopsy by two pathologists. The diagnostic criteria to classify a patient as an HBV carrier were as follows: HBsAg (+), HBV DNA (+), HBeAg or anti-HBeAb (+), and with normal level of ALT and AST, and no abnormal histological biopsy. All serum samples were drawn using a K3 EDTA anticoagulation tube and stored at 4°C in the freezer after centrifuging at 2500 rpm × 15 min The blood plasma of the upper layer was taken using suction and the samples were stored at -80°C.

Reagents
--------

Micro Bio Spin column and protein assay reagents were from Bio-Rad (Hercules, CA). Mouse anti-human GAPDH antibody was purchased from Sigma Co. Ltd., Mouse anti-human enolase 1, TSP-1 and secondary antibody were purchased from Santa Cruz Co. Ltd. ProteoExtract^®^ Subcellular Proteome Extraction Kit was purchased from MERCK Co. Ltd.

Methods
-------

### Serum sample preparation

All serum samples were transported on ice and centrifuged at 3000 g for 15 min at 4°C. The supernatants were stored at -80°C until further analysis. Serum samples from two patients with HBV hepatic fibrosis and two HBV carriers were used for the proteomics study. The serum samples from the other four patients with HBV hepatic fibrosis and four HBV carriers were used for the western blotting study.

### 2-DE electrophoresis

Albumin was first removed from the serum samples prior to electrophoresis. 60 μl serum were added into 180 μl combined buffer for 15 min. And Albumin were separated by adsorbing into the spin column. Collecting the supernatant fluid and used for 2-DE. The operation of 2-DE was conducted according to the ProteoExtract^®^ Subcellular Proteome Extraction Kit manual. Serum samples of 1000 μg were mixed with rehydration solution \[7 mol/L urea, 2 mol/L thiourea, 0.2% DTT, 0.5% (v/v) pH3-10 IPG buffer, and a trace of bromophenol blue in a total volume of 450 μl\]. Then, the samples were applied to IPG strips (pH 3-10L, 24 cm) by 14 h rehydration at 30 V, 1 h at 500 V, 1 h at 1000 V and 8.5 h at 8000 V to give a total of 68 kVh on IPGphor. Focused IPG strips were equilibrated for 15 min in a solution of 6 mol/L urea, 2% SDS, 30% glycerol, 50 mmol/L Tris--HCl (pH 8.8), and 1% DTT, and then a further 15 min in the same solution except that DTT was replaced by 2.5% iodoacetamide. IPG strips were removed after isoelectric focusing and placed into 10 ml of equilibrium A fluid \[50 mmol/L Tris--HCl pH8.8, 6 mol/L urea, 30% glycerol, 1% SDS, 0.2% DTT, trace quantities of bromophenol blue\] and then 10 ml equilibrium B fluid \[50 mmol/L Tris--HCl pH8.8, 6mol/L urea, 30% glycerol, 1% SDS, 3% iodoacetamide, trace quantities of bromophenol blue\], and equilibrated for 15 min each. SDS-PAGE was performed on an Ettan DALT II system. The protein samples were degenerated for 3 min in 100°C boiling water and then the samples were added into the top hole of a 12.5% PAGE separation gel on the Ettan DALT II system. Electrophoresis was performed at 2.5W for 30 min and then 17W until the samples reached the bottom margin of the PAGE separation gel. G-250 was used to visualize the protein spots in the 2-DE gels.

### Image analysis

2-DE gels were scanned by an Images Scanner used MagicScan software (Amersham Biosciences) and analyzed by the PDQuest system (Bio-Rad Laboratories). Three separate gels were prepared for each cell line. The gel spot pattern of each gel was summarized in a standard gel after spot matching. Thus, we obtained one standard gel for each sample. The intensities of the spots were quantified by calculation of spot volume after normalization of the image using the total spot volume normalization method multiplied by the total area of all the spots. Proteins were identified as being differentially expressed when the spot intensity showed a difference of 2-fold. Significant differences were determined by the Student's test with a set value of P \< 0.05.

### Protein identification by MS

All the differential spots were excised from the stained 2-DE gels using a punch. An aliquot of 1 ml 50% methyl cyanide and 50 mol/L (NH~4~)~2~CO~3~ were used to decolorize gels at 37°C for 30 min in a water bath. The tryptic peptide (0.1 μg/ml) was mixed with an R-cyano-4-hydroxycinnamic acid matrix solution. One microliter of the mixture was analyzed with a Voyager System DE-STR 4307 MALDI-TOF Mass Spectrometer (ABI) to obtain a peptide mass fingerprint (PMF). All the data were searched in a peptide mass fingerprint map database and Mascot Distiller was used to obtain the monoisotopic peak list from the raw mass spectrometry files.

From the tandem mass spectrometry database query, the peptide sequence tag (PKL) format file that was generated from MS/MS was imported into the Mascot search engine (<http://www.matrixscience.com>) with a MS/MS tolerance of (±0.3 Da) to search against SwissProt 2012_05 database (536,029 sequences; 190, 235, 160 residues). The parameters were selected as follows:Enzyme: Trypsin; Variable modifications: Carbamidomethyl (C), Oxidation (M); Mass values: Monoisotopic; Protein Mass: Unrestricted; Peptide Mass Tolerance: ± 0.3 Da; Fragment Mass Tolerance: ± 0.3 Da. Those proteins with scores \>61 were identified as being different proteins (p \< 0.05).

### Western blotting

The final protein concentration was measured by the Bradford method \[[@B8]\]. A 40 μg serum protein sample was used for the gel electrophoresis in a 12% PAGE separation gel on an Ettan DALT II system. Then the samples were electrotransferred onto a PVDF membrane. Blots were blocked with 5% nonfat dry milk for 2 h at room temperature, and then incubated with primary anti-enolase 1, anti-TSP-1 for 2 h at room temperature, followed by incubation with a horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The signal was visualized with an enhanced chemiluminescence detection reagent and quantitated by densitometry using an ImageQuant image analysis system (Storm Optical Scanner, Molecular Dynamics). The mouse anti-enolase 1 (1:4000, Sigma) and anti-TSP-1(1:4000, Sigma) were detected simultaneously as loading controls.

Results
=======

Establishment of 2-DE maps of HBV carrier and hepatic fibrosis
--------------------------------------------------------------

We obtained 38 differentially expressed spots with ≥2 fold difference between HBV carriers and hepatic fibrosis patients. The spots were detected by MS and 27 differentially expressed proteins were determined (Figure [1](#F1){ref-type="fig"}). Figure [1](#F1){ref-type="fig"}C provides a closer view of the maps of some of the differentially expressed proteins.

![**Representative serum 2-DE maps of HBV hepatic fibrosis and HBV carriers. A**. Map of HBV hepatic fibrosis. **B**. Map of HBV carriers. The protein spots marked with arrows are the twenty-seven differential protein spots identified by MS. **C**. Close-up of the region of the gels showing some of the proteins differentially expressed between HBV hepatic fibrosis patients and HBV carriers.](1477-5956-11-30-1){#F1}

2.2 MS identification of differentially expressed proteins. A total of 27 differentially expressed proteins were identified by MALDI-TOF-MS (Table [1](#T1){ref-type="table"}). The data were searched in the SwissProt 2012_05 (536,029 sequences; 190,235,160 residues) database using the Mascot search engine. Enolase-1 was identified as one of the differentially expressed proteins and its mass finger print and Mascot search results are shown in Figure [2](#F2){ref-type="fig"}. The identified proteins are involved in cell growth, receptor binding, metastasis, blood coagulation, calcium ion binding, and DNA binding as well as some were enzymes and biomarkers (Table [1](#T1){ref-type="table"}).

###### 

Differential expressed proteins identified by MALDI-TOF-MS between serum of HBV hepatic fibrosis and HBV carriers

  **Spot**   **Accession number**   **Protein name**                                   **Mass weight**   **pI**   **Sequence coverage (%)**   **Scores**   **Ratio**^**\***^   **Function**
  ---------- ---------------------- -------------------------------------------------- ----------------- -------- --------------------------- ------------ ------------------- ----------------------
  1          P02771                 Alpha-fetoprotein                                  69500             5.31     19                          203          ↑2.01               biomarker
  2          P08833                 Insulin-like growth factor-binding protein 1       33200             4.9      23                          262          ↑2.01               Cell growth
  3          P02741                 C-reactive protein                                 23760             5.12     23                          570          ↑2.02               calcium binding
  4          P19838                 Nuclear factor NF-kappa-B p105 subunit             105356            6.09     18                          186          ↑2.02               DNA binding
  5          P2671                  Fibrinogen alpha chain                             66818             7.65     8                           298          ↑2.03               receptor binding
  6          Q03135                 Caveolin-1                                         20472             6.95     9                           78           ↑2.03               enzyme activity
  7          P05121                 Plasminogen activator inhibitor 1                  48577             6.77     12                          138          ↑2.11               blood coagulation
  8          P00505                 Aspartate aminotransferase                         47476             4.87     19                          110          ↑2.26               catalytic activity
  9          P01137                 Transforming growth factor beta-1                  40412             5.86     12                          188          ↑2.29               Cell growth
  10         P04271                 Protein S100-B                                     10713             4.43     8                           154          ↑2.31               calcium binding
  11         P24298                 Alanine aminotransferase 1                         54637             5.11     13                          908          ↑2.89               catalytic activity
  12         Q14116                 Interleukin-18                                     21326             5.23     27                          392          ↑2.97               signal transducer
  13         P01375                 Tumor necrosis factor                              25644             5.43     18                          152          ↑3.01               apoptotic process
  14         P08253                 Matrix metallopeptidase 2                          73882             6.57     30                          150          ↑3.01               metastasis
  15         P01579                 Interferon gamma                                   19348             5.67     16                          335          ↑3.21               receptor binding
  16         P01034                 Cystatin-C                                         13120             7.11     13                          262          ↑3.57               enzyme activity
  17         P05187                 Alkaline phosphatase                               57954             6.14     16                          362          ↑3.66               hydrolase activity, 
  18         P01033                 Metalloproteinase inhibitor 1                      23171             5.28     4                           74           ↑4.21               metastasis
  19         P07996                 Thrombospondin-1                                   25695             6.67     6                           166          ↑7.56               blood coagulation
  20         P17936                 Insulin-like growth factor-binding protein 3       31674             5.03     8                           304          ↓2.17               Cell growth
  21         P37231                 Peroxisome proliferator-activated receptor gamma   57620             5.23     25                          946          ↓2.72               DNA binding
  22         P04180                 Phosphatidylcholine-sterol acyltransferase         49578             5.68     17                          541          ↓2.88               catalytic activity
  23         P06276                 Cholinesterase                                     68418             6.92     16                          765          ↓3.12               catalytic activity
  24         P02652                 Apolipoprotein A-II                                12520             4.74     28                          552          ↓3.22               receptor binding
  25         O46409                 Apolipoprotein A-IV                                43294             5.74     26                          550          ↓3.57               receptor binding
  26         Q6Q788                 Apolipoprotein A-V                                 41213             4.97     13                          394          ↓3.59               receptor binding
  27         P19875                 Enolase-1                                          47481             7.01     12                          252          ↓5.09               DNA binding

^\*^ Hepatic fibrosis vs HBV carriers.

![**MALDI-TOF-MS analysis of differential protein spot 27. A**. The MALDI-TOF-MS mass spectrum of spot 27; **B**. Mascot search results of spot 27, which was identified as enolase-1 according to the matched peaks; **C**. The protein sequence coverage and matched peptides of enolase-1.](1477-5956-11-30-2){#F2}

2.3 Verification of differentially expression proteins by western blot. The two proteins, enolase-1 and thrombospondin-1(TSP-1) were detected by western blot in the serum of hepatic fibrosis patients and HBV carriers. Enolase-1 was at least 5.09-fold down-regulated in hepatic fibrosis patients compared to HBV carriers and TSP-1 was at least 7.56-fold up-regulated in hepatic fibrosis patients compared to HBV carriers. Enolase-1 and TSP-1 were detected in eight cases (four hepatic fibrosis patients and four HBV carriers). The results showed that, compared to HBV carriers, expression of enolase-1 was down regulated in the serum of patents with hepatic fibrosis, while expression of TSP-1 was up regulated in the serum of patients with hepatic fibrosis (Figure [3](#F3){ref-type="fig"}). The results of western blot confirmed the results from the proteomics study.

![**Western blots of Enolase-1 and TSP-1 in the serum of hepatic fibrosis patients and HBV carriers. A**, Western blot analysis showing changes in the expression level of enolase 1 and TSP-1 in the serum of HBV carriers and hepatic fibrosis patients. **B**, Histogram shows the expression level of the proteins in the serum of HBV carriers and hepatic fibrosis patients as analyzed by Bandleader 3.0 software. Note: bands 1, 2, 3, and 4 are from HBV carriers and bands 5, 6, 7, and 8 are from HBV hepatic fibrosis patients.](1477-5956-11-30-3){#F3}

Discussion
==========

Hepatic fibrosis is an inevitable process in the transformation of chronic HBV infection to hepatic cirrhosis, but its detailed mechanism is still unknown. Fontana et al. retrospectively analyzed the clinical progression of serum hepatic fibrosis markers obtained from currently laboratory methods and discovered that these clinical test methods can only reliably recognize advanced fibrosis, and cannot accurately identify the degree of fibrosis present during the early and middle portions of its progression \[[@B9]\]. Therefore, identification of HBV hepatic fibrosis biomarkers is of great significance for early diagnosis and prevention of fibrosis.

Serum proteomics studies serum proteins which are readily available. However, because of proteome analysis restrictions for sample size, highly abundant proteins often make it difficult to separation and identify less abundant proteins, an issue which is particularly evident in the proteomic analyses of serum \[[@B10]\]. Thus, it is necessary to first remove the interfering high abundance proteins prior to serum proteome analysis. In this study, we removed the albumin which improves the detection rate of low abundance proteins with good reproducibility. A total of 27 differentially expressed genes were found in patients with HBV hepatic fibrosis compared to the plasma of HBV carriers, of which 19 were up-regulated and 8 were down-regulated in the serum of patients with HBV hepatic fibrosis.

As one of the key enzymes of glycolysis, enolase-1 (α-enolase) widely exists in many tissues and its expression varies with cellular pathological physiology, metabolism, inflammation, and the state of cell development \[[@B11],[@B12]\]. Enolase-1 also plays an important role in cell energy metabolism \[[@B13]\]. Enolase-1 is expressed at the cell surface where it promotes cancer invasion, and is subjected to a specific array of post-translational modifications, namely acetylation, methylation and phosphorylation. Enolase-1 binds plasminogen at the cell surface, enhancing local plasmin production and monocyte migration through epithelial monolayers, and promoting matrix degradation. These data suggest an important mechanism of inflammatory cell invasion is mediated by increased cell-surface expression of enolase-1 \[[@B14]\]. Both enolase-1 over expression and its post-translational modifications could be of diagnostic and prognostic value in cancer \[[@B15]\]. Takashima et al. analyzed the hepatic tissue of patients with hepatitis b virus-related hepatocellular carcinoma (HCC) by proteomics analysis and found that expression of enolase-1 was enhanced, which is particularly apparent in poorly-differentiated HCC \[[@B16]\]. Enolase-1 acts as a central element in colon cancer susceptibility and protein biosynthesis \[[@B17]\]. However there are no reports about enolase-1 and hepatic fibrosis. Our experimental results indicated that the expression level of enolase-1 in the serum of patients with HBV hepatic fibrosis was significantly higher than that in HBV carriers. Its change of concentration in the blood may reflect the degree of hepatic fibrosis suggesting that enolase-1 can be used as a serum marker for the prediction of hepatic fibrosis.

Thrombospondin-1 (TSP-1) is a glycoprotein with a molecular weight of 450 kDa, and is a major component of platelets \[[@B18]\]. It is involved in angiogenesis and inflammation and the effects of TSP-1 have been studied in numerous preclinical tumor models. Many normal cells, including endothelial cells, fibroblasts, adipocytes, smooth muscle cells, monocytes, and macrophages were all founded to secrete TSP-1 \[[@B19],[@B20]\]. TSP-1 binds to the protein components of the extracellular matrix such as fibronectin. TSP-1 is also expressed in glomerulopathies and is considered an early marker of inflammation and fibrosis \[[@B21]\].

TSP-1 can bind to various receptors and functions in regulating cell proliferation, proteases and the activity of transforming growth factor beta-1 (TGF-β1) \[[@B22],[@B23]\]. As an activator of TGF-β1, TSP-1 modulates the functions of TGF-β1 in cardiovascular diseases, atherosclerosis, and obesity. In addition, TSP-1 is selectively expressed in the infracted border suggesting that TSP-1 might inhibit the expansion of inflammation by activating TGF-β1 \[[@B24]\]. TSP1 is also a major endogenous activator of TGF-β1 in experimental inflammatory glomerular disease. Regulation of TSP-1 with regards to its influence on TGF-β1 activity may be one of the causes of fibrosis, as TGF-β1 positively regulates HCV RNA replication which is likely manifested in the liver fibrosis associated with hepatitis C infection \[[@B25]\]. It has been reported that TSP-1 is closely related to renal fibrosis in which TSP-1 is highly expressed \[[@B26]\]. In studies of hepatic fibrosis, TSP-1 is found to be highly expressed. TSP-1 might play an additional role in liver fibrogenesis by stimulating angiogenesis and could be a potential target to prevent fibrogenesis in chronic inflammatory diseases of the liver \[[@B27]\].

NF-κB is a transcription factor present in almost all animal cell types. It is involved in many biological processes such as inflammation, immunity, cell differentiation, cell growth, tumorigenesis and apoptosis \[[@B28]\]. Studies indicate that NF-κB and TSP-1 together, modulated by the expression of the androgen receptor, exert antitumor effects in prostate cancer \[[@B29]\]. In the tumor microenvironment, TSP-1 has been shown to suppress tumor growth by inhibiting angiogenesis and activating TGF-β1. NF-κB mRNA expression and activity were significantly enhanced by proteinuria-loading and were synchronized with high expression of TSP-1, and TGF-β1 mRNA in the kidney \[[@B30]\]. We found that expression of TSP-1, TGF-β1, and NF-κB in patients with HBV hepatic fibrosis were all significantly higher than that in the serum of HBV carriers, suggesting that TSP-1, TGF-β1, and NF-κB play important roles in the process of hepatic fibrosis. The detailed mechanisms involved in the interplay between TSP-1, TGF-β1, NF-κB and hepatic fibrosis require further study.

In conclusion, using a proteomics method, we obtained 27 differentially expressed proteins by comparing the serum of HBV carriers and hepatic fibrosis patients. The 27 proteins identified by proteomic methods are involved in cell growth, receptor binding, metastasis, blood coagulation, calcium ion binding, DNA binding, as well as being biomarkers and enzymes. Additional work is required to understand the relationship between these proteins and hepatic fibrosis. The results indicated that TSP-1, TGF-β1, NF-κB, and enolase-1 likely play important roles in the process of hepatic fibrosis. Although the levels of enolase-1 and TSP-1 in the serum of HBV carriers and hepatic fibrosis patients can be detected, the relationship between the degree of liver fibrosis and their expression needs further study.
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